Molecular Pathology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guerra, I
Right arrow Articles by Fariña, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guerra, I
Right arrow Articles by Fariña, J
Molecular Pathology 2003;56:323-327
© 2003 BMJ Publishing Group Ltd & Association of Clinical Pathologists


ORIGINAL ARTICLE

Immunohistochemical prognostic index for breast cancer in young women

I Guerra1, J Algorta2, R Díaz de Otazu1, A Pelayo3 and J Fariña3

1 Servicio de Anatomía Patológica, Hospital Txagorritxu, c/ José Achótegui s/n, 01009 Vitoria-Gasteiz, Spain
2 Unidad Ensayos Clínicos (Fundación LEIA), Hospital Txagorritxu
3 Cátedra de Anatomía Patológica II. Hospital Clínico de San Carlos, 28972 Madrid, Spain

Correspondence to:
Dr I Guerra
Servicio Anatomía Patológica, Hospital Txagorritxu, c/ José Achótegui s/n, 01009 Vitoria-Gasteiz, Spain; iguerra{at}htxa.osakidetza.net

Aims: Women under 35 years of age comprise a small proportion of patients with breast cancer, but determining their prognosis can be difficult. This prospective, multivariate study looked at several factors with the aim of obtaining a useful index to evaluate the prognosis of these women.

Methods: In total, 108 patients below 35 years of age affected by invasive ductal carcinoma without distant metastasis were studied. The mean duration of the follow up period was six years. Histopathological (tumour size, histological grade, and lymph node stage) and immunohistochemical (c-erbB-2, p53, oestrogen receptor, and progesterone receptor) factors were measured in all patients, and the Nottingham prognostic index (NPI) was then calculated. An immunohistochemical prognostic index (IHPI) was created using the arithmetic sum of the four individual immunohistochemical factors.

Results: In univariate assessment of survival, all the studied factors yielded a significant association with either overall survival or disease free survival, except for c-erbB-2 and p53 with disease free survival. In univariate calculation of risk, all the factors gave significant results; however, in multivariate analysis only tumour size, histological grade, and progesterone receptor were significant. Both NPI and IHPI correlated significantly with prognosis. In multivariate regression analysis, IHPI correlated with tumour size and there was a significant interaction between both variables.

Conclusion: IHPI is very useful in determining the prognosis of tumours <= 2 cm and of moderate use for tumours > 2, although it has no use in tumours > 5 cm.


Keywords: young women; breast cancer; immunohistochemical prognostic index; c-erbB-2; p53; oestrogen receptor; progesterone receptor; Nottingham prognostic index

Abbreviations: ER, oestrogen receptor; IHPI, immunohistochemical prognostic index; NPI, Nottingham prognostic index; PR, progesterone receptor







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Molecular Pathology Journal of Clinical Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.